Is aspirin treatment an appropriate intervention for osteoporosis?

Future Rheumatology

Volumn 3, Issue 6, 2008, Pages 499-502

  Yamaza, Takayoshi ^a   Akiyama, Kentaro ^a   Shi, Songtao ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; FAS LIGAND; OSTEOCLAST DIFFERENTIATION FACTOR;

APOPTOSIS; BONE METABOLISM; CD4+ CD45+ T LYMPHOCYTE; DRUG MECHANISM; EDITORIAL; ENTERITIS; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; NONHUMAN; OSTEOBLAST; OSTEOCYTE; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 70350090509     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.3.6.499     Document Type: Editorial

References (43)

1. Raisz LG: Pathogenesis of osteoporosis: concepts, conflict, and prospects. J. Clin. Invest. 115, 3318-3325 (2005).
2. Walsh MC, Kim N, Kadono Y et al.: Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 24, 33-63 (2006).
3. Weitzmann MN, Pacici R: The role of T lymphocytes in bone metabolism. Immunol Rev. 208, 154-168 (2005).
4. Clowes JA, Riggs BL, Khosla S: The role of the immune system in the pathophysiology of osteoporosis. Immunol. Rev. 208, 207-227 (2005).
5. Hock JM, Krishnan V, Onyia JE et al.: Osteoblast apoptosis and bone turnover. J. Bone Miner. Res. 16, 975-984 (2001).
6. Manolagas SC: Cell number versus cell vigor what really matters to a regenerating skeleton Endocrinology 140, 4377-4381 (1999).
7. Xing L, Boyce BF: Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys. Res. Commun. 328, 709-720 (2005).
8. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC: Quantifying osteoblast and osteocyte apoptosis: challenge and rewards. J. Bone Miner. Res. 22, 1492-1501 (2007).
9. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV: Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17, 331-340 (1974).
10. Owen M, Friedenstein AJ: Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found. Symp. 136, 42-60 (1988).
11. Prockop DJ: Marrow stromal cells as stem cells for non-hematopoietic tissues. Science 276, 71-74 (1997).
12. Tanaka Y, Nakayamada S, Okada Y: Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr. Drug Targets Inflamm. Allergy 4, 325-328 (2005).
13. Zhang J, Niu C, Ye L et al.: Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425, 836-841 (2003).
14. Calvi LM, Adams GB, Weibrecht KW et al.: Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841-846 (2003).
15. Arai F, Hirano A, Ohmura M et al.: Tie2/angiopoietin-1 signalling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118, 149-161 (2004).
16. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822 (2005).
17. Bartholomew A, Sturgeon C, Siatskas M et al.: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30, 42-48 (2002).
18. Uccelli A, Pistoia V, Moretta L: Mesenchymal stem cells: A new strategy for immunosuppression? Trends Immunol. 28, 219-226 (2007).
19. Corcione A, Benvenuto F, Ferretti E et al.: Human mesenchymal stem cells modulate B-cell functions. Blood 107, 367-372 (2006).
20. Rasmusson I, Le Blanc K, Sundberg B, Ringdén O: Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand. J. Immunol. 65, 336-343 (2007).
21. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F: Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83, 71-76 (2007).
22. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L: Mesenchymalstemcell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107, 1484-1490 (2006).
23. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822 (2005).
24. Le Blanc K, Rasmusson I, Sundberg B et al.: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363, 1439-1441 (2004).
25. Chen X, Armstrong MA, Li G: Mesenchymal stem cells in immunoregulation. Immunol. Cell Biol. 84, 413-421 (2006).
26. Koç ON, Gerson SL, Cooper BW et al.: Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol. 18, 307-316 (2000).
27. Noort WA, Kruisselbrink AB, in't Anker PS et al.: Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34 cells in NOD/SCID mice. Exp. Hematol. 30, 870-878 (2002).
28. Scholz M, Cinatl J: Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals. Med. Res. Rev. 25, 331-342 (2005).
29. Brunner T, Wasem C, Torgler R et al.: Fas (CD95/Apo-1) ligand regulation in T-cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin. Immunol. 15, 167-176 (2003).
30. Yamaza T, Miura Y, Bi Y et al.: Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS ONE 3(7), e2615 (2008).
31. Kataoka T, Shinohara N, Takayama H et al.: Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin and Fas-based lytic pathways in cell-mediated cytotoxicity. J. Immunol. 156, 3678-3686 (1996).
32. Kogianni G, Mann V, Ebetino F et al.: Fas/CD95 is associated with glucocorticoid-induced osteocyte apoptosis. Life Sci. 75, 2879-2895 (2004).
33. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL: Phenotypically distinct subsets of CD41 T cells induce or protect from chronic intestinal in?ammation in CB-17 SCID mice. Int. Immunol. 5, 1461-1471 (1993).
34. Morrissey PJ, Charrier K, Braddy S, Liggitt D, Watson JD: CD41 T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD41 T cells. J. Exp. Med. 178, 237-244 (1993).
35. Read S, Malmstrom V, Powrie F: Cytotoxic T-lymphocyte associated antigen 4 plays an essential role in the function of CD251CD41 regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000).
36. Sylvester FA: IBD and skeletal health: children are not small adults! Inflamm. Bowel Dis. 11, 1020-1023 (2005).
37. Rothfuss KS, Stange EF, Herrlinger KR: Extraintestinal manifestations and complications in inflammatory bowel diseases. World J. Gastroenterol. 12, 4819-4831 (2006).
38. Roggia C, Gao Y, Cenci S et al.: Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl Acad. Sci. USA 98, 13960-13965 (2001).
39. Carbone LD, Tylavsky FA, Cauley JA et al.: Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J. Bone Miner. Res. 18, 1795-1802 (2003).
40. Bauer DC, Orwoll ES, Fox KM et al.: Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk: study of osteoporotic fractures research group. J. Bone Miner. Res. 11, 29-35 (1996).
41. Miura M, Chen X-D, Allen MR et al.: A crucial role of Caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J. Clin. Invest. 114, 1704-1713 (2004).
42. Bode-Boger SM, Martens-Lobenhoffer J, Tager M, Schroder H, Scalera F: Aspirin reduces endothelial cell senescence. Biochem. Biophys. Res. Commun. 334, 1226-1232 (2005).
43. Shi S, Gronthos S, Chen S, Counter CM, Robey PG, Wang CY: Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat. Biotechnol. 20, 587-591 (2002).